Clonal Hematopoiesis and Atherosclerosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

29 citing papers in PubMed.

1. Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.American journal of hematology · 2026
   Review
2. Clonal haematopoiesis and risk of incident rheumatoid arthritis: results from the UK Biobank.Clinical and experimental rheumatology · 2026
   Article
3. Science advances · 2025
   Article
4. Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis.Scientific reports · 2024
   Article
5. Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial.Blood advances · 2024 · on this map
   Article
6. Clonal hematopoiesis in frequent whole blood donors.Hematology. American Society of Hematology. Education Program · 2023
   Article
7. Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS.Cell reports. Medicine · 2023
   Article
8. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.American journal of hematology · 2023
   Review
9. Clonal hematopoiesis and ischemic stroke.Blood · 2023
   Article
10. Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19.Blood · 2022
    Article
11. VEXAS Syndrome and Disease Taxonomy in Rheumatology.Arthritis & rheumatology (Hoboken, N.J.) · 2022
    Article
12. Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond.Rheumatology (Oxford, England) · 2022
    Review
13. Somatic Mutations and Clonal Hematopoiesis as Drivers of Age-Related Cardiovascular Risk.Current cardiology reports · 2022
    Review
14. Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome.Haematologica · 2022
    Article
15. Endothelial Senescence and the Chronic Vascular Diseases: Challenges and Therapeutic Opportunities in Atherosclerosis.Journal of personalized medicine · 2022
    Review
16. Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.Haematologica · 2021
    Article
17. Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality.ESC heart failure · 2021
    Article
18. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics.Nature reviews. Genetics · 2021
    Review
19. The myeloid type I interferon response to myocardial infarction begins in bone marrow and is regulated by Nrf2-activated macrophages.Science immunology · 2020
    Article
20. TET family dioxygenases and the TET activator vitamin C in immune responses and cancer.Blood · 2020
    Review

Corrections and comments

• Comment on
  Clonal Hematopoiesis and Atherosclerosis.2017
• Comment on
  Clonal Hematopoiesis and Atherosclerosis.2017

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as